Schick, M. | Search bioRxiv

bioRxiv2021

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance. The pro-apoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype. To identify drugs that unleash the death-inducing potential of NOXA, we performed an unbiased drug screening experiment. In NOXA-deficient isogenic cellular models we identified an inhibitor of the transcription factor heterodimer CBF{beta}/RUNX1. By genetic gain and loss of function experiments we validated that the mode of action depends on RUNX1 and NOXA. Of note, RUNX1 expression is significantly higher in PDACs compared to normal pancreas. We show that pharmacological RUNX1 inhibition significantly blocks tumor growth in vivo and in primary patient-derived PDAC organoids. Through genome wide analysis, we detected that RUNX1-loss reshapes the epigenetic landscape, which gains H3K27ac enrichment at the NOXA promoter. Our study demonstrates a previously unknown mechanism of NOXA-dependent cell death, which can be triggered pharmaceutically. Therefore, our data show a novel way to target a therapy resistant PDAC, an unmet clinical need. SignificanceRecent evidence demonstrated the existence of molecular subtypes in pancreatic ductal adenocarcinoma (PDAC), which resist all current therapies. The paucity of therapeutic options, including a complete lack of targeted therapies, underscore the urgent and unmet medical need for the identification of targets and novel treatment strategies for PDAC. Our study unravels a function of the transcription factor RUNX1 in apoptosis regulation in PDAC. We show that pharmacological RUNX1 inhibition in PDAC is feasible and leads to NOXA-dependent apoptosis. The development of targeted therapies that influence the transcriptional landscape of PDAC might have great benefits for patients who are resistant to conventional therapies. RUNX1 Inhibition as a new therapeutic intervention offers an attractive strategy for future therapies.

cancer biology↗

bioRxiv2019

Model Plasma Membrane exhibits a Microemulsion in both Leaves providing a Foundation for \"Rafts\"

We consider a model plasma membrane, one that describes the outer leaf as consisting of sphingomyelin, phosphatidylcholine, and cholesterol, and the inner leaf of phosphatidylethanolamine, phosphatidylserine, phosphatidyl-choline, and cholesterol. Their relative compositions are taken from experiment, and the cholesterol freely interchanges between leaves. Fluctuations in composition are coupled to fluctuations in the membrane height as in the Leibler-Andelman mechanism. Provided that the membrane is of relatively constant thickness, this coupling of fluctuations also provides a coupling between the composition fluctuations of the two leaves. Structure functions display, for components in both leaves, a peak at non-zero wavevector. This indicates that the disordered fluid membrane is characterized by structure on a scale given by membrane properties. From measurements on the plasma membrane, this scale is on the order of 100 nm. The theory provides a tenable basis for the origin of \"rafts\".\n\nStatement of SignificanceThe hypothesis that the plasma membrane is not homogeneous, but rather is heterogeneous, with rafts\" of one composition floating in a sea of another, has overturned conventional views of this membrane and how it functions. Proteins prefer either the raft or the sea, and so are not uniformly distributed. Hence they perform more efficiently. From experiment, rafts are thought to be about 100 nm. However there is no realistic model that provides: a length scale for the rafts; a raft in both leaves of the membrane; the composition of the raft. We provide such a model. In contrast to other theories, the raft and sea are distinguished not only by composition, but also by a difference in curvature.

biophysics↗